Publications An expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials Citation Almradi A, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. 2021 Apr;53(7):784-793. doi: 10.1111/apt.16248. Epub 2021 Jan 7. PMID: 33410551. Abstract Background: Targeting histological remission or response in Crohn’s disease (CD) is not recommended in clinical practice guidelines or as an outcome in clinical trials due to uncertainties regarding index validity and prognostic relevance. Tags Clinical Trials, Colon, Crohn's Disease, Treatment Outcome Read More
